BeOne Medicines (ONC) Income from Continuing Operations (2015 - 2026)
BeOne Medicines (ONC) reported Income from Continuing Operations of 227357000.0 for Q1 2026, up 17802.13% year-over-year from N/an in Q1 2025, and up 241.88% on a QoQ basis from 66502000.0 in Q4 2025.
BeOne Medicines (ONC) has 12 years of Income from Continuing Operations data on file, last reported at 227357000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 17802.13% year-over-year to 227357000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 513020000.0 (up 230.75% YoY) and the FY2025 annual result came in at 286933000.0, up 144.5% from the prior year.
- Income from Continuing Operations grew to 227357000.0 in Q1 2026 per ONC's latest filing, from 66502000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 227357000.0 in Q1 2026 and bottomed at 565726000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 151881000.0 (2024), against an average of 177412882.35.
- The widest annual swing landed in 2022, when Income from Continuing Operations slumped 754.48%; it then soared 17802.13% in 2026.
- Tracing ONC's Income from Continuing Operations over 5 years: stood at 445335000.0 in 2022, then rose by 17.47% to 367553000.0 in 2023, then surged by 58.68% to 151881000.0 in 2024, then surged by 143.79% to 66502000.0 in 2025, then soared by 241.88% to 227357000.0 in 2026.
- Per Business Quant, the three latest ONC Income from Continuing Operations figures stand at 227357000.0 (Q1 2026), 66502000.0 (Q4 2025), and 124841000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 227.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.36 Mn |
| Dec 31, 2025 | 66.50 Mn |
| Sep 30, 2025 | 124.84 Mn |
| Jun 30, 2025 | 94.32 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | -151.88 Mn |
| Sep 30, 2024 | -121.35 Mn |
| Jun 30, 2024 | -120.41 Mn |
| Mar 31, 2024 | -251.15 Mn |
| Dec 31, 2023 | -367.55 Mn |
| Sep 30, 2023 | 215.41 Mn |
| Jun 30, 2023 | -381.14 Mn |
| Mar 31, 2023 | -348.43 Mn |
| Dec 31, 2022 | -445.34 Mn |
| Sep 30, 2022 | -557.56 Mn |
| Jun 30, 2022 | -565.73 Mn |
| Mar 31, 2022 | -435.20 Mn |
| Dec 31, 2021 | -590.68 Mn |
| Sep 30, 2021 | -438.11 Mn |
| Jun 30, 2021 | -480.34 Mn |
| Mar 31, 2021 | 66.50 Mn |
| Dec 31, 2020 | -500.72 Mn |
| Sep 30, 2020 | -426.62 Mn |
| Jun 30, 2020 | -336.32 Mn |
| Mar 31, 2020 | -364.94 Mn |
| Dec 31, 2019 | -387.90 Mn |
| Sep 30, 2019 | -308.66 Mn |
| Jun 30, 2019 | -85.95 Mn |
| Mar 31, 2019 | -168.07 Mn |
| Dec 31, 2018 | -266.71 Mn |
| Sep 30, 2018 | -144.49 Mn |
| Jun 30, 2018 | -157.72 Mn |
| Mar 31, 2018 | -105.12 Mn |
| Dec 31, 2017 | -99.28 Mn |
| Sep 30, 2017 | 117.28 Mn |
| Jun 30, 2017 | -60.68 Mn |
| Mar 31, 2017 | -50.62 Mn |
| Dec 31, 2016 | -37.60 Mn |
| Sep 30, 2016 | -35.49 Mn |
| Jun 30, 2016 | -24.12 Mn |
| Mar 31, 2016 | -22.00 Mn |
| Dec 31, 2015 | 24.60 Mn |
| Sep 30, 2015 | -14.00 Mn |
| Jun 30, 2015 | -5.64 Mn |
| Mar 31, 2015 | -10.21 Mn |